Updates in nonhormonal therapy for perimenopausal and menopausal symptoms.

IF 2.2 4区医学 Q2 OBSTETRICS & GYNECOLOGY

Current Opinion in Obstetrics & Gynecology Pub Date : 2025-04-01 Epub Date: 2025-01-13 DOI:10.1097/GCO.0000000000001009

Amy J Voedisch

{"title":"Updates in nonhormonal therapy for perimenopausal and menopausal symptoms.","authors":"Amy J Voedisch","doi":"10.1097/GCO.0000000000001009","DOIUrl":null,"url":null,"abstract":"Purpose of review: Perimenopausal and menopausal symptoms are common and may significantly impact quality of life. Menopausal hormone therapy is the most effective treatment but may not be appropriate in all cases. Nonhormonal alternatives range from lifestyle changes and dietary supplements to medical interventions and prescription therapies. This review will summarize the newest advancements in nonhormonal therapies for bothersome perimenopausal and menopausal symptoms.Recent findings: The Menopause Society recently updated their recommendations and guidelines for nonhormonal therapies. Previous recommendations, such as clonidine and pregabalin, are no longer recommended. A new class of medication, neurokinin B antagonists, are now available to target vasomotor symptoms and show promise in addressing sleep and mood issues.Summary: Well tolerated, effective nonhormonal therapies are available to address perimenopausal and menopausal symptoms for those patients who are not candidates for or chose not to use menopausal hormone therapy.","PeriodicalId":55194,"journal":{"name":"Current Opinion in Obstetrics & Gynecology","volume":" ","pages":"67-74"},"PeriodicalIF":2.2000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Obstetrics & Gynecology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/GCO.0000000000001009","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Perimenopausal and menopausal symptoms are common and may significantly impact quality of life. Menopausal hormone therapy is the most effective treatment but may not be appropriate in all cases. Nonhormonal alternatives range from lifestyle changes and dietary supplements to medical interventions and prescription therapies. This review will summarize the newest advancements in nonhormonal therapies for bothersome perimenopausal and menopausal symptoms.

Recent findings: The Menopause Society recently updated their recommendations and guidelines for nonhormonal therapies. Previous recommendations, such as clonidine and pregabalin, are no longer recommended. A new class of medication, neurokinin B antagonists, are now available to target vasomotor symptoms and show promise in addressing sleep and mood issues.

Summary: Well tolerated, effective nonhormonal therapies are available to address perimenopausal and menopausal symptoms for those patients who are not candidates for or chose not to use menopausal hormone therapy.

查看原文本刊更多论文

围绝经期和更年期症状的非激素治疗的最新进展。

综述的目的：围绝经期和更年期症状是常见的，并可能显著影响生活质量。更年期激素治疗是最有效的治疗方法，但并非适用于所有病例。非激素替代方案包括从生活方式改变和膳食补充剂到医疗干预和处方疗法。本文将对非激素治疗恼人的围绝经期和更年期症状的最新进展进行综述。最近的发现：更年期协会最近更新了他们对非激素治疗的建议和指南。以前的推荐，如可乐定和普瑞巴林，不再被推荐。一类新的药物，神经激肽B拮抗剂，现在可用于血管舒缩症状，并显示出解决睡眠和情绪问题的希望。总结：对于那些不适合或选择不使用绝经期激素治疗的患者，可以使用耐受性良好、有效的非激素治疗来解决围绝经期和绝经期症状。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Obstetrics & Gynecology 医学-妇产科学

CiteScore

4.10

自引率

0.00%

发文量

104

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Obstetrics and Gynecology is a bimonthly publication offering a unique and wide ranging perspective on the key developments in the field. Each issue features hand-picked review articles from our team of expert editors. With eleven disciplines published across the year – including reproductive endocrinology, gynecologic cancer and fertility– every issue also contains annotated references detailing the merits of the most important papers.